Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Nano Meeting Is Just The Beginning of Supplement, OTC Questions

This article was originally published in The Tan Sheet

Executive Summary

Rather than draft a potentially "onerous rule" based on insufficient current information about the use of nanotechnology in dietary supplements, OTC drugs and other products, FDA needs additional safety data to determine if guidance is even necessary, a leading industry scientist says

You may also be interested in...

Nanomaterials public meeting

FDA will conduct a public meeting Sept. 8 to discuss regulated products that may contain nanoscale materials and request public comment on how to implement the recommendations of the Nanotechnology Task Force Report, according to an Aug. 7 Federal Register notice. In the notice, the agency asks for comment on proper assessment tools to evaluate nanomaterials, manufacturing processes for products containing nanomaterials and for personal accounts of experiences with nanoscale materials. Comments are due Oct. 24. The Nanotechnology Task Force issued its recommendations to FDA in July 2007 (1"The Tan Sheet" July 30, 2007, p. 12)...

J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores

J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.

Ensuring Leading Position For GSK Consumer Products Touted In Management Shift

GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts